Variantyx Secures $20M in Funding
The series C funding round was led by GHS Fund (Quark Venture LP and GF Securities) and includes new investor, IBM Ventures and current investors, Pitango Venture Capital, New Era Capital Partners, 20/20 HealthCare Partners. Zafrira Avnur, PhD, Quark Venture Chief Scientific Officer & Partner, will join the Variantyx board of directors.
OnKure Raises $55 Million Series B Funding
Proceeds will be used to advance the Company’s next generation histone deacetylase (HDAC) inhibitors further into clinical development and fund a growing pipeline of earlier stage molecules.
YishengBio Raises $130 Million in Series B Funding
This round of funding will strongly support the expansion of the company's R&D center, accelerate their commercialization strategies including the clinical development of multiple vaccine candidates, and the construction of biologics production facilities in China and Singapore.
Electromedical Technologies Secures $1Mil for Product Expansion
The company secured a $1 million investment by a fund managed by Yorkville Advisors Global, LP to complete prototype production of its WellnessPlus POD
Teon Therapeutics Completes $30 Million Series A Financing
Financing was led by Oceanpine Capital with participation from additional new investors Oriza Ventures, Lifespan Investments, and former Gilead senior executives.
Sciwind Biosciences Secures US$37 Million Series B Financing
Sciwind Biosciences notes financing was led by LYFE Capital and joined by the existing investors, Legend Capital and Haibang Venture Capital.